NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols

Leukemia

Volumn 24, Issue 12, 2010, Pages 2014-2022

  Zuurbier, L ^a   Homminga, I ^a   Calvert, V ^b   Winkel, Ml Te ^a   Buijs Gladdines, J G C A M ^a   Kooi, C ^a   Smits, W K ^a   Sonneveld, E ^c   Veerman, A J P ^c   Kamps, W A ^c,d   Horstmann, M ^e,f   Petricoin, E F ^b,g   Pieters, R ^a   Meijerink, J P P ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b GEORGE MASON UNIVERSITY   (United States)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

FBXW7; NOTCH1; outcome; pediatric T ALL; prednisone response; TLX3

Indexed keywords

ANKYRIN; FBXW7 PROTEIN; GENOMIC DNA; METHOTREXATE; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PREDNISONE; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL ASSESSMENT; CYTOGENETICS; DUTCH CHILDHOOD ONCOLOGY GROUP; EXON; FEMALE; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; GENE REARRANGEMENT; GERMAN COOPERATIVE STUDY GROUP FOR CHILDHOOD; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MICROARRAY; RNA EXTRACTION; SCHOOL CHILD; SINGLE DRUG DOSE;

EID: 78650307928     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.204     Document Type: Article

References (46)

1. Pieters R, Carroll WL. Biology and treatment of acute lympho-blastic leukemia. Pediatr Clin North Am 2008; 55: 1-20, ix.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
3. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2004; 103: 442-450.
4. Meijerink JP, den Boer ML, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 16-23.
5. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 2008; 143: 153-168.
6. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66: 649-661.
7. Suzuki S, Nagel S, Schneider B, Chen S, Kaufmann M, Uozumi K et al. A second NOTCH1 chromosome rearrangement: t(9;14)(q34.3;q11.2) in T-cell neoplasia. Leukemia 2009; 23: 1003-1006.
8. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
9. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008; 112: 733-740.
10. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
11. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266.
12. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-2109.
13. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616.
14. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204: 1813-1824.
15. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145: 198-206.
16. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
17. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157.
18. Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu J et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006; 12: 3043-3049.
19. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008; 22: 124-131.
20. 0s Oncology Group. Leukemia 2009; 23: 1417-1425.
21. Kamps WA, Bokkerink JP, Hahlen K, Hermans J, Riehm H, Gadner H et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 1999; 94: 1226-1236.
22. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16: 1099-1111.
23. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
24. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P et al. The outcome of molecu-lar-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006; 91: 1212-1221.
25. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 1270-1276.
26. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
27. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108: 3520-3529.
28. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lympho-blastic leukemia. Blood 2008; 111: 4668-4680.
29. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-818.
30. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31-36.
31. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW et al. Reverse-phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-1989.
32. Petricoin 3rd EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007; 67: 3431-3440.
33. Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, Kim SH et al. Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer 2006; 42: 2369-2373.
34. Homminga I, langerak AW, De Laat W, de Rooij JJ, Stubbs A, Buijs-Gladdines J et al. NKX2-1 and MEF2C oncogenes delineate novel subtypes in T-cell acute lymphoblastic leukemia. (in preparation).
35. 0 Heureux S, Romany C et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.
36. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009; 113: 3918-3924.
37. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27: 4352-4356.
38. Gordon WR, Roy M, Vardar-Ulu D, Garfinkel M, Mansour MR, Aster JC et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 2009; 113: 4381-4390.
39. Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003; 102: 1000-1006.
40. Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood 2008; 111: 376-378.
41. Mansour MR, Duke V, Foroni L, Patel B, Allen CG, Ancliff PJ et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res 2007; 13: 6964-6969.
42. Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G et al. Prognostic significance of NOTCH1 and FBXW7 mutations in childhood T-cell acute leukemia: results from the EORTC Children Leukemia Group. Leukemia 2010, (this issue).
43. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50-58.
44. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL can be seperated from NOTCH pathway activation by FBXW7 loss of function. Leukemia 2010, (this issue).
45. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009; 94: 1383-1390.
46. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459: 1000-1004.